Microbion Corp
Microbion Corp is a clinical-stage pharmaceutical company focused on developing a novel class of compounds to treat difficult-to-treat infections, including chronic and antibiotic-resistant infections. Their lead therapeutic candidate, Pravibismane, is a groundbreaking anti-infective drug with broad-spectrum activity and a unique mechanism that halts microbial cellular metabolism. The company is committed to providing physicians with innovative options to improve and extend patients' lives, addressing key unmet medical needs with their site-specific delivery approach that enhances efficacy and safety while reducing antibiotic resistance risks.
Microbion Corp
5 West Mendenhall Street, Suite 202, Bozeman, MT 59715
What We Do
Pravibismane is the first in a new class of anti-infective drugs with broad-spectrum activity and a novel mechanism of action that halts microbial cellular metabolism. It is effective in preventing and eradicating biofilms that contribute to chronic infection and facilitate antibiotic resistance. The company has two Phase 2 clinical stage programs for topical/local treatment of diabetic foot ulcer infection and orthopedic device-related infection, and one pre-clinical program for the inhalation treatment of chronic lung infection.
Key People
Founder, President & Chief Innovation Officer
Chief Scientific Officer
Senior Director, New Product Planning and Business Operations
Director of Finance
News & Updates
The study achieved its primary endpoint, demonstrating safety and tolerability of a 12-week treatment regimen with high-concentration of topical pravibismane. High patient compliance was observed with at-home self-treatment, and data demonstrated a numerical treatment benefit across multiple efficacy measures.
Microbion won the Innovation Showcase Award at the Advanced Wound Care Summit USA 2024 for their presentation on topical pravibismane’s clinical safety and efficacy for the treatment of moderate to severe diabetic foot ulcer infection.
Microbion was one of six finalists selected to present at the Advanced Wound Care Summit’s Innovation Showcase session, focusing on topical pravibismane’s clinical safety and efficacy for the treatment of moderate to severe diabetic foot infection.
Microbion received the Innovation Showcase Award for their work on topical pravibismane, highlighting its potential impact on treating infected diabetic foot ulcers.